Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France
Status: Recruiting
Location: See all (40) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• ≥18 years of age
• Physician-reported diagnosis of moderate to severe plaque psoriasis
• Be newly initiating deucravacitinib
• Do not object to participate
Locations
Other Locations
France
Local Institution - 060
NOT_YET_RECRUITING
Amiens
Cabinet Médical Elisabeth Lion
RECRUITING
Angers
Local Institution - 045
NOT_YET_RECRUITING
Argenteuil
CH ARRAS
RECRUITING
Arras
Local Institution - 041
NOT_YET_RECRUITING
Bordeaux
Local Institution - 048
NOT_YET_RECRUITING
Bordeaux
Centre Hospitalier William Morey - Hématologie
RECRUITING
Chalon-sur-saône
CHU Dijon
RECRUITING
Dijon
Local Institution - 077
NOT_YET_RECRUITING
Dijon
Local Institution - 011
NOT_YET_RECRUITING
La Tronche
Local Institution - 074
NOT_YET_RECRUITING
Le Puy-en-velay
Local Institution - 039
NOT_YET_RECRUITING
Lens
Local Institution - 004
NOT_YET_RECRUITING
Marcq-en-barœul
Local Institution - 036
NOT_YET_RECRUITING
Montpellier
Local Institution - 012
NOT_YET_RECRUITING
Nice
Local Institution - 062
NOT_YET_RECRUITING
Nîmes
Local Institution - 008
NOT_YET_RECRUITING
Niort
Local Institution - 070
NOT_YET_RECRUITING
Niort
Local Institution - 073
NOT_YET_RECRUITING
Paris
Local Institution - 078
NOT_YET_RECRUITING
Périgueux
Local Institution - 046
NOT_YET_RECRUITING
Roubaix
Local Institution - 047
NOT_YET_RECRUITING
Roubaix
Local Institution - 051
NOT_YET_RECRUITING
Saint-mandé
Local Institution - 072
NOT_YET_RECRUITING
Saint-maur-des-fossés
Hia Sainte Anne
RECRUITING
Toulon
Local Institution - 054
NOT_YET_RECRUITING
Toulon
Local Institution - 005
NOT_YET_RECRUITING
Toulouse
Local Institution - 021
NOT_YET_RECRUITING
Toulouse
Local Institution - 037
NOT_YET_RECRUITING
Toulouse
Local Institution - 061
NOT_YET_RECRUITING
Vandœuvre-lès-nancy
Local Institution - 064
NOT_YET_RECRUITING
Vandœuvre-lès-nancy
Local Institution - 003
NOT_YET_RECRUITING
Villeurbanne
Local Institution - 006
NOT_YET_RECRUITING
Villeurbanne
Switzerland
Cabinet Medical
RECRUITING
La Chaux-de-fonds
Cabinet Medical
RECRUITING
La Chaux-de-fonds
Local Institution - 007
NOT_YET_RECRUITING
La Chaux-de-fonds
Local Institution - 025
NOT_YET_RECRUITING
La Chaux-de-fonds
Local Institution - 029
NOT_YET_RECRUITING
La Chaux-de-fonds
Local Institution - 038
NOT_YET_RECRUITING
La Chaux-de-fonds
Local Institution - 044
NOT_YET_RECRUITING
La Chaux-de-fonds
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2025-01-29
Estimated Completion Date: 2028-04-30
Participants
Target number of participants: 350
Treatments
Participants that have initiated deucravacitinib treatment
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb